Wellness CTR USA Inc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 1 of 1 Posts
Depomed To Acquire U.S. Rights To NUCYNTA®, NUCYNTA® ER; Amgen Presents First-Line Use Of Vectibix®
Article By: BioMedReports Friday, January 16, 2015 3:44 AM EDT
Depomed Inc. announced it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion.
In this article: DEPO, AMGN, DDD, ADXS, ALDX, AMBS, AMED, BSDM, BMRN, CBMG, DVCR, GALE, GB, HTBX, HEB, ISRG, OMED, PMCB, PRGB, RGDX, TGTX, WCUI
Read
1 to 1 of 1 Posts